With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since the first infection was reported in the U.S., the country’s total number of cases has surpassed both that of Italy and China, and the Trump administration is calling on names in the space to step in. The sector’s response? Challenge accepted. As the U.S. government pumped $8.3 billion into research as well as prevention efforts, several biotech companies have joined the fight against COVID-19. Among those battling the virus, one of TipRanks’ top five rated investing firms, Oppenheimer, recently highlighted two biotech heavyweights that have made notable strides in developing COVID-19 drugs. Bearing this in mind, we used TipRanks’ database to learn more about Oppenheimer’s picks. It turns out that each Buy-rated ticker has also received substantial support from other Wall Street analysts. Here’s the...
With the number of confirmed COVID-19 cases rising despite worldwide lockdowns and social distancing efforts, the biotech industry is taking action. In just two months since the first infection was reported in the U.S., the country’s total number of cases has surpassed both that of Italy and China, and the Trump administration is calling on names in the space to step in. The sector’s response? Challenge accepted. As the U.S. government pumped $8.3 billion into research as well as prevention efforts, several biotech companies have joined the fight against COVID-19. Among those battling the virus, one of TipRanks’ top five rated investing firms, Oppenheimer, recently highlighted two biotech heavyweights that have made notable strides in developing COVID-19 drugs. Bearing this in mind, we used TipRanks’ database to learn more about Oppenheimer’s picks. It turns out that each Buy-rated ticker has also received substantial support from other Wall Street analysts. Here’s the...
Despite last week’s impressive gains, there are still some skeptics calling for renewed selling pressure on the Nikkei 225 Index after a rise in domestic coronavirus cases stoked worries of tougher domestic restrictions for social distancing....
Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit's malaria, lupus and arthritis drug hydroxychloroquine is the company's biggest hope against the coronavirus, Swiss newspaper SonntagsZeitung reported on Sunday. Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which U.S. President Donald Trump also has been promoting, can be approved for use against the coronavirus. Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus....
